Blood Group Incompatibilities and Hemolytic Complications of Hematopoietic Cell Transplantation

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 1219-1225

  O'Donnell, Margaret R ^a  

^a Division of Hematology and Hematopoietic Cell Transplantation   (United States)

Author keywords

Blood group incompatibilities and hemolytic complications of hematopoietic cell transplantation; Criteria for thrombotic microangiopathy (TM); Delayed hemolytic reactions; Hemolysis and TM syndrome; Hemolytic complications of ABO incompatibility; Management of ABO and Rh incompatibility; Therapy for post HCT TM

Indexed keywords

EID: 84890707217     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch81     Document Type: Chapter

References (88)

1. Buckner CD, Clift RA, Sanders JE, Gray W, Storb R, Thomas ED. ABO incompatible marrow transplants. Transplantation 1978; 26: 233-8.
2. Rowley SD, Liang PS, Ulz L. Transplantation of ABO-incompatible bone marrow and peripheral blood stem cell components. Bone Marrow Transplant 2000; 26: 749-57.
3. Salmon JP, Michaux S, Hemanne JP et al. Delayed massive immune hemolysis mediated by minor ABO incompatibility after allogeneic peripheral blood progenitor cell transplantation. Transfusion 1999; 39: 824-7.
4. Warkentin PI, Yomtovian R, Hurd D et al. Severe delayed hemolytic transfusion reaction complicating an ABO-incompatible bone marrow transplantation. Vox Sang 1983; 45: 40-7.
5. Hows J, Beddow K, Gordon-Smith E et al. Donor derived RBC antibodies and immune hemolysis after allogeneic BMT. Blood 1986; 67: 177-81.
6. Blacklock HA, Katz F, Michalevicz R et al. A and B blood group antigen expression on mixed colony cells and erythroid precursors: relevance for human allogeneic bone marrow transplantation. Br J Haematol 1984; 58: 267-76.
7. Benjamin RJ, Connors JM, McGurk S, Churchill WH, Antin JH. Prolonged erythroid aplasia after major ABO-mismatched transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant 1998; 4: 151-6.
8. Lee JH, Lee KH, Kim S et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25: 179-84.
9. Barge AJ, Johnson G, Witherspoon R, Torok-Storb B. Antibody-mediated marrow failure after allogeneic bone marrow transplantation. Blood 1989; 74: 1477-80.
10. Slavin S, Nagler A, Naparstek E et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-63.
11. McSweeney P, Niederwieser D, Shiauru J et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing highdose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-400.
12. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-6.
13. Worel N, Greinix HT, Schneider B et al. Regeneration of erythropoiesis after related and unrelated donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion 2000; 40: 543-50.
14. Bolan C, Leitman S, Griffith L et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood 2001; 98: 1687-94.
15. Badros A, Tricot G, Toor A et al. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion 2002; 45: 205-9.
16. Maciej Zaucha J, Mielcarek M, Takatu A et al. Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABOincompatible hematopoietic stem cell transplantation. Br J Haematol 2002; 119: 740-50.
17. Griffith LM, McCoy JP Jr, Bolan CD et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible nonmyeloablative haematopoietic cell transplantation. Br J Haematol 2005; 128: 668-75.
18. Peggs K, Morris E, Kottaridis P et al. Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen. Blood 2002; 99: 4642-3.
19. Lee JH, Lee JH, Choi SJ et al. Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. Br J Haematol 2003; 120: 702-10.
20. Bornhauser M, Ordemann R, Paaz U et al. Rapid engraftment after allogeneic ABO-incompatible peripheral blood progenitor cell transplantation complicated by severe hemolysis. Bone Marrow Transplant 1997; 19: 295-7.
21. Moog R, Melder C, Prumbaum M, Muller N, Schaefer UW. Rapid donor type isoagglutinin production after allogeneic peripheral progenitor cell transplantation. Beitr Infusionsther Transfusionsmed 1997; 34: 150-2.
22. Young PP, Goodnough LT, Westervelt P, DiPersio JF. Immune hemolysis involving non-ABO/RhD alloantibodies following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 1305-10.
23. de la Rubia J, Arriaga F, Andreu R et al. Development of non-ABO RBC alloantibodies in patients undergoing allogeneic HPC transplantation: is ABO incompatibility a predisposing factor? Transfusion 2001; 4: 106-10.
24. Franchini M, de Gironcoli M, Gandini G et al. Transmission of an anti-RhD alloantibody from donor to recipient after ABO-incompatible BMT. Bone Marrow Transplant 1998; 21: 1071-3.
25. Leo A, Mytilineos J, Voso MT et al. Passenger lymphocyte syndrome with severe hemolytic anemia due to an anti-Jka after allogeneic PBPC transplantation. Transfusion 2000; 40: 632-6.
26. Snell M, Chau C, Hendrix D et al. Lack of isohemagglutinin production following minor ABO incompatible unrelated HLA mismatched umbilical cord blood transplantation. Bone Marrow Transplant 2006; 38: 135-40.
27. Lapierre V, Kuentz M, Tiberghien P. Allogeneic peripheral blood hematopoietic stem cell transplantation: guidelines for red blood cell immuno-hematological assessment and transfusion practice. Société Française Greffe Moelle. Bone Marrow Transplant 2000; 25: 507-12.
28. Besinger WI, Deeg JH. Transfusion support and donor consideration in marrow transplantation. In: Sacher RA, Aubuchon JP, editors. Marrow Transplantation: Practical and Technical Aspects of Stem Cell Reconstitution. Bethesda, MD: American Association of Blood Banks; 1992. pp. 157-79.
29. Petz LD. Immune hemolysis association with transplantation. Semin Hematol 2005; 42: 145-55.
30. Larsson LG, Welsh VJ, Ladd DJ. Acute intravascular hemolysis secondary to out-of-group platelet transfusion. Transfusion 2000; 40: 902-6.
31. Webb IJ, Soiffer RJ, Anderson JW et al. In vivo adsorption of isohemagglutinins with fresh frozen plasma in major ABO-incompatible bone marrow transplantation. Biol Blood Marrow Transplant 1997; 3: 267-72.
32. Nussbaumer W, Schwaighofer H, Gratwohl A et al. Transfusion of donor-type red cells as a single preparative treatment for bone marrow transplants with major ABO incompatibility. Transfusion 1995; 35: 592-5.
33. Mielcarek M, Leisenring W, Torok-Storb B, Storb R. Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Blood 2000; 96: 1150-6.
34. Remberger M, Watz E, Ringden O, Mattsson J, Shamwell A, Wikman A. Major ABO blood group mismatch increases the risk for graft failure after unrelated donor HCT. Biol Blood Marrow Transplant 2007; 13: 675-82.
35. Benjamine RJ, McGurk S, Ralston MS et al. ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. Transfusion 1999; 39: 179-87.
36. Seebach JD, Stussi G, Passweg JR et al. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant 2005; 11: 1006-13.
37. Volin L, Ruutu T. Pure red-cell aplasia of long duration after major ABO-incompatible bone marrow transplantation. Acta Haematol 1990; 84: 195-7.
38. Taniguchi S, Yamasaki K, Shibuya T, Asayama R, Harada M, Niho Y. Recombinant human erythropoietin for long-term persistent anemia after major ABO incompatible bone marrow transplantation. Bone Marrow Transplant 1993; 12: 423.
39. Paltiel O, Cournoyer D, Rybka W. Pure red cell aplasia following ABO-incompatible bone marrow transplantation: response to erythropoietin. Transfusion 1993; 33: 418-21.
40. Santamaria A, Sureda A, Martino R, Domingo-Albos A, Muniz-Diaz E, Brunet S. Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin. Bone Marrow Transplant 1997; 20: 1105-7.
41. Bavaro P, Di Girolamo G, Olioso P et al. Donor lymphocyte infusion as therapy for pure red cell aplasia following bone marrow transplantation. Br J Haematol 1999; 104: 930-1.
42. Sora F, De Matteis S, Piccirillo N et al. Rituximab for pure red cell aplasia after ABO-mismatched allogeneic peripheral blood progenitor cell transplantation. Transfusion 2005; 45: 643-5.
43. Verholen F, Stalder M, Heig C, Chalandon Y. Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion. Eur J Haematol 2004; 73: 441-6.
44. Selleri C, Raiola A, De Rosa D et al. CD34+-enriched donor lymphocyte infusions in a case of pure red cell aplasia and late graft failure after major ABO-incompatible bone marrow transplantation. Bone Marrow Transplant 1998; 22: 605-7.
45. Geetha D, Zachary B, Baldardo H, Kronz J, Kraus E. Pure red cell aplasia caused by parvovirus B19 infection in solid organ transplant recipients: a case report and review of literature. Clin Transplant 2000; 14: 586-91.
46. Misra S, Moore T, Ament M, Busuttil R, McDiarmid S. Red cell aplasia in children on tacrolimus after liver transplantation. Transplantation 1998; 65: 575-7.
47. Engelen W, Verpooten GA, Van der Planken M, Helbert MF, Bosmans JL, De Boe ME. Four cases of red blood cell aplasia in association with the use of mycophenolate mofetil in renal transplant patients. Clin Nephrol 2003; 60: 119-24.
48. Anasetti C, Rybka W, Sullivan KM et al. Graftversus-host disease is associated with autoimmunelike thrombocytopenia. Blood 1989; 73: 1054-8.
49. Drobyski WR, Potluri J, Sauer D, Gottschall JL. Autoimmune hemolytic anemia following T celldepleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 17: 1093-9.
50. Haug C, Duell T, Lenich A, Kolb HJ, Grunert A. Elevated plasma endothelin concentrations in cyclosporine-treated patients after bone marrow transplantation. Bone Marrow Transplant 1995; 15: 191-4.
51. Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104: 100-6.
52. Seeber C, Hiller E, Holler E, Kolb HJ. Increased levels of tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor (PAI) correlate with tumor necrosis factor alpha release in patients suffering from microangiopathy following bone marrow transplantation. Thromb Res 1992; 66: 373-83.
53. Biedermann BC, Sahner S, Gregor M et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002; 359: 2078-83.
54. Chappell ME, Keeling DM, Prentice HG, Sweny P. Haemolytic uraemic syndrome after bone marrow transplantation: an adverse effect of total body irradiation? Bone Marrow Transplant 1988; 3: 339-47.
55. Guinan EC, Tarbell NJ, Niemeyer CM et al. Intravascular hemolysis and renal insufficiency after bone marrow transplantation. Blood 1998; 72: 451-5.
56. Rabinowe SN, Soiffer RJ, Tarbell NJ et al. Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood 1991; 77: 1837-44.
57. Juckett M, Perry EH, Daniels BS, Weisdorf DJ. Hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 1991; 7: 405-9.
58. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994; 14: 495-504.
59. Van der Lelie H, Baars JW, Rodenhuis S et al. Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support. Cancer 1995; 76: 2338-42.
60. Holler E, Kolb JH, Hiller F et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLAidentical bone marrow transplantation. Blood 1989; 73: 2018-24.
61. Moake J. Thrombotic microangiopathies. N Engl J Med 2002; 34: 589-600.
62. Kwann HC, Ganguly P. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Semin Hematol 1997; 34: 81-148.
63. Van der Plas RM, Schiphorst M, Huizinga E et al. Von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantationassociated, thrombotic thrombocytopenic purpura. Blood 1999; 93: 3798-802.
64. George JN, Li X, McMinn JR et al. Thrombotic thrombocytopenia purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 2004; 44: 294-304.
65. Tarantolo SR, Landmark JD, Hinrichs SH et al. Bartonella-like erythrocyte inclusions associated with post-transplant thrombotic microangiopathy: improved survival with doxycycline. Blood 1997; 90: 252a.
66. Cutler C, Henry NL, Magee C et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 551-7.
67. Uderzo C, Bonanomi S, Busca A et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 2006; 82: 638-44.
68. Nakamae H, Yamane T, Hasegawa T et al. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol 2006; 81: 525-31.
69. Hale GA, Bowman LC, Rochester RJ et al. Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children. Biol Blood Marrow Transplant 2005; 11: 912-20.
70. Oran B, Donato M, Aleman A et al. Transplantassociated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant 2007; 13: 469-77.
71. Shimoni A, Yeshurun M, Hardan I et al. Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: the incidence is not reduced. Biol Blood Marrow Transplant 2004; 10: 484-93.
72. Elliott MA, Nicholas WLJ, Plumhoff EA et al. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clin Proc 2003; 78: 421-30.
73. Ho VT, Cutler C, Carter S et al. Blood and Marrow Transplant Clinical Trials Network Toxicity Committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571-5.
74. Ruutu T, Barosi G, Benjamin RJ et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007; 92: 95-100.
75. Imoto S, Murayama T, Nagai K et al. Usefulness of sequential automated analysis of fragmented red blood cells for the differential diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic hematopoietic cell transplantation. Lab Hematol 2005; 11: 131-6.
76. Zeigler ZR, Rosenfeld CS, Andrews DF et al. Plasma von Willebrand factor antigen (vWF: AG) and thrombomodulin (TM) levels in adult thrombotic thrombocytopenic purpura/hemolytic uremic syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM). Am J Hematol 1996; 53: 213-20.
77. Peyvandi F, Siboni SM, Lambertenghi Deliliers D et al. Prospective study on the behavior of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation. Br J Haematol 2006; 134: 187-95.
78. Rock GA. Management of thrombotic thrombocytopenic purpura. Br J Haematol 2000; 109: 496-507.
79. Snyder HW, Mittelman A, Oral A et al. Treatment of cancer chemotherapy related thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer 1993; 71: 1882-92.
80. Sarode R, McFarland JG, Flomenberg N et al. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 1995; 16: 271-5.
81. Zeigler ZR, Shadduck RK, Nath R, Andrews DE. Pilot study of combined cryosupernatant and protein A immunoadsorption exchange in the treatment of grade 3-4 bone marrow transplant-associated thrombotic microangiopathy. Bone Marrow Transplant 1996; 17: 81-6.
82. Roy V, Rizvi MA, Vesely SK, George JN. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 2001; 27: 641-6.
83. Silva VA, Frei-lahr D, Brown RA, Herzig GP. Plasma exchange and vincristine in the treatment of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura associated with bone marrow transplantation. J Clin Apheresis 1991; 6: 16-20.
84. Dua A, Zeigler ZR, Shadduck RK, Nath R, Andrews DF, Agha M. Apheresis in grade 4 bone marrow transplant associated thrombotic microangiopathy: a case series. J Clin Apheresis 1996; 11: 176-84.
85. Llamas P, Romero R, Cabrera R, Sanjuan I, Fores R, Fernandez MN. Management of thrombotic microangiopathy following allogeneic transplantation: what is the role of plasma exchange? Bone Marrow Transplant 1997; 20: 305-6.
86. Milone J, Napal J, Bordone J, Etchegoyen O, Morales V. Complete response in severe thrombotic microangiopathy post bone marrow transplantation (BMT-TM) after multiple plasmaphereses. Bone Marrow Transplant 1998; 22: 1019-21.
87. Ruutu T, Hermans J, Niederwieser D et al. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002; 118: 1112-19.
88. Eissner G, Multhoff G, Gerbitz A et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood 2002; 100: 334-40.